[Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity

Rhea-AI Filing Summary

Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics, reported a single non-derivative transaction on 09/22/2025. The Form 4 shows a sale of 688 shares of Abeona common stock at $5.43 per share, executed to cover tax obligations tied to the vesting of restricted stock awards. After the sale, Mr. O'Malley is reported to beneficially own 360,129 shares directly. The filing is submitted by one reporting person and is signed by Mr. O'Malley on 09/22/2025. The disclosure is limited to this transaction and its stated tax-related purpose.

Positive

• Transaction purpose disclosed: The Form 4 explicitly states the sale was to cover tax obligations related to vested restricted stock awards, increasing transparency.
• Modest disposal size: The 688-share sale is small relative to the reported post-transaction holding of 360,129 shares, suggesting limited impact on insider ownership.
• Timely and complete filing: The form includes transaction date, price, quantity, role of reporting person, and signature dated 09/22/2025.

Negative

• Insider sale occurred: Any insider sale reduces insider-held shares, which some investors may view negatively despite the tax-related reason.

Insights

Financial Analyst

TL;DR Insider sold a small number of shares to cover taxes; ownership remains substantial and no unusual trading pattern is evident.

The sale of 688 shares at $5.43 is modest relative to the reported post-transaction holding of 360,129 shares, indicating this was a routine tax-covering disposition rather than a larger liquidity event. The filing provides clear price and quantity details and ties the sale explicitly to RSU vesting tax obligations, which reduces interpretive ambiguity. No derivative transactions or additional changes in ownership are reported.

Corporate Governance Expert

TL;DR Proper Section 16 disclosure completed for a routine, tax-related insider sale; governance transparency standards met.

The Form 4 discloses the reporting persons officer role and director status and records the transaction date, price, and purpose (tax withholding for vested restricted stock). The signature and single-reporting-person indicator comply with filing norms. There is no evidence in this filing of compensatory changes, policy shifts, or material corporate actions requiring further governance scrutiny.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Malley Brendan M.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		S(1)		688	D	$5.43	360,129	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

	/s/ Brendan O'Malley	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Brendan M. O'Malley report on the Form 4 for ABEO?

He reported a sale of 688 shares of Abeona common stock on 09/22/2025 at a price of $5.43 per share.

Why were the shares sold according to the filing?

The filing states the sale was to cover tax obligations associated with the vesting of restricted stock awards.

How many Abeona shares does Mr. O'Malley own after the transaction?

The Form 4 reports he beneficially owns 360,129 shares following the reported sale.

What is Brendan O'Malleys role at Abeona Therapeutics as listed on the form?

He is listed as SVP, Chief Legal Officer and as a Director/Officer of the company.

When was the Form 4 signed and filed?

The form is signed by Brendan O'Malley and dated 09/22/2025.